PL372769A1 - Proleki cyjanoguanidynowe - Google Patents
Proleki cyjanoguanidynoweInfo
- Publication number
- PL372769A1 PL372769A1 PL03372769A PL37276903A PL372769A1 PL 372769 A1 PL372769 A1 PL 372769A1 PL 03372769 A PL03372769 A PL 03372769A PL 37276903 A PL37276903 A PL 37276903A PL 372769 A1 PL372769 A1 PL 372769A1
- Authority
- PL
- Poland
- Prior art keywords
- sub
- prodrugs
- cyanoguanidine
- cyanoguanidine prodrugs
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
Abstract
Przedmiotem wynalazku są związki pirydylocyjanoguanidynowe o wzorze I, w którym A, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, Y<sub>1</sub>, Y<sub>2</sub>, Y<sub>3</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub>, R<sub>6</sub>, i n mają znaczenie podane w opisie wynalazku. Związki powyższe są użyteczne jako proleki w terapii u ludzi i terapii weterynaryjnej choroby proliferacyjnej takiej jak raki.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38083602P | 2002-05-17 | 2002-05-17 | |
US60/380,836 | 2002-05-17 | ||
PCT/DK2003/000318 WO2003097601A1 (en) | 2002-05-17 | 2003-05-15 | Cyanoguanidine prodrugs |
Publications (2)
Publication Number | Publication Date |
---|---|
PL372769A1 true PL372769A1 (pl) | 2005-08-08 |
PL228742B1 PL228742B1 (pl) | 2018-05-30 |
Family
ID=29550021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL372769A PL228742B1 (pl) | 2002-05-17 | 2003-05-15 | Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070249676A1 (pl) |
EP (1) | EP1507760B1 (pl) |
JP (1) | JP4625694B2 (pl) |
KR (1) | KR101010871B1 (pl) |
CN (1) | CN100503570C (pl) |
AT (1) | ATE368649T1 (pl) |
AU (1) | AU2003229534B2 (pl) |
BR (1) | BR0309996A (pl) |
CA (1) | CA2485351C (pl) |
DE (1) | DE60315288T2 (pl) |
ES (1) | ES2290454T3 (pl) |
HK (1) | HK1076812A1 (pl) |
IL (1) | IL165086A (pl) |
IS (1) | IS7562A (pl) |
MX (1) | MXPA04011322A (pl) |
NO (1) | NO330183B1 (pl) |
PL (1) | PL228742B1 (pl) |
RU (1) | RU2326867C2 (pl) |
WO (1) | WO2003097601A1 (pl) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253193B2 (en) | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
ES2572777T3 (es) | 2004-12-22 | 2016-06-02 | Leo Pharma A/S | Compuestos novedosos de cianoguanidina |
WO2007022964A2 (de) | 2005-08-24 | 2007-03-01 | Abbott Gmbh & Co. Kg | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
WO2009072004A2 (en) * | 2007-09-26 | 2009-06-11 | Gemin X Pharmaceuticals Canada, Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
JP5688367B2 (ja) | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブTopoTarget A/S | 新規なウレアおよびチオウレア誘導体 |
WO2010088842A1 (zh) | 2009-02-06 | 2010-08-12 | 天津和美生物技术有限公司 | 含有吡啶基氰基胍的药物组合物及其制备和应用 |
WO2011006988A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
ES2779225T3 (es) * | 2011-04-08 | 2020-08-14 | Sphaera Pharma Pte Ltd | Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos |
MX2015000101A (es) * | 2012-06-27 | 2015-06-22 | Alzheimer S Inst Of America Inc | Compuestos y usos terapéuticos de los mismos. |
CN116640238B (zh) * | 2023-05-30 | 2024-05-03 | 华侨大学 | 一种胍基吡啶壳聚糖鎓盐及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
AU4076500A (en) * | 1999-04-09 | 2000-11-14 | Shionogi Bioresearch Corp. | (n)-substituted cyanoguanidine compounds |
AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
RU2004136989A (ru) * | 2002-05-17 | 2005-06-27 | Лео Фарма А/С (Dk) | Цианогуанидиновые пролекарства |
-
2003
- 2003-05-15 RU RU2004136991/04A patent/RU2326867C2/ru active
- 2003-05-15 MX MXPA04011322A patent/MXPA04011322A/es active IP Right Grant
- 2003-05-15 AT AT03722311T patent/ATE368649T1/de not_active IP Right Cessation
- 2003-05-15 DE DE60315288T patent/DE60315288T2/de not_active Expired - Lifetime
- 2003-05-15 ES ES03722311T patent/ES2290454T3/es not_active Expired - Lifetime
- 2003-05-15 JP JP2004505334A patent/JP4625694B2/ja not_active Expired - Fee Related
- 2003-05-15 PL PL372769A patent/PL228742B1/pl unknown
- 2003-05-15 KR KR1020047018603A patent/KR101010871B1/ko active IP Right Grant
- 2003-05-15 CA CA2485351A patent/CA2485351C/en not_active Expired - Lifetime
- 2003-05-15 EP EP03722311A patent/EP1507760B1/en not_active Expired - Lifetime
- 2003-05-15 CN CNB038140772A patent/CN100503570C/zh not_active Expired - Fee Related
- 2003-05-15 AU AU2003229534A patent/AU2003229534B2/en not_active Ceased
- 2003-05-15 BR BR0309996-2A patent/BR0309996A/pt not_active Application Discontinuation
- 2003-05-15 WO PCT/DK2003/000318 patent/WO2003097601A1/en active IP Right Grant
-
2004
- 2004-11-08 IL IL165086A patent/IL165086A/en active IP Right Grant
- 2004-11-29 IS IS7562A patent/IS7562A/is unknown
- 2004-12-08 NO NO20045374A patent/NO330183B1/no not_active IP Right Cessation
-
2005
- 2005-10-10 HK HK05108938.3A patent/HK1076812A1/xx not_active IP Right Cessation
-
2007
- 2007-06-28 US US11/823,571 patent/US20070249676A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070249676A1 (en) | 2007-10-25 |
AU2003229534A1 (en) | 2003-12-02 |
DE60315288D1 (de) | 2007-09-13 |
PL228742B1 (pl) | 2018-05-30 |
JP4625694B2 (ja) | 2011-02-02 |
NO20045374L (no) | 2004-12-08 |
RU2004136991A (ru) | 2005-06-10 |
BR0309996A (pt) | 2005-02-22 |
CN100503570C (zh) | 2009-06-24 |
CA2485351C (en) | 2011-12-06 |
IS7562A (is) | 2004-11-29 |
EP1507760A1 (en) | 2005-02-23 |
KR101010871B1 (ko) | 2011-01-26 |
IL165086A (en) | 2011-11-30 |
DE60315288T2 (de) | 2008-04-10 |
NO330183B1 (no) | 2011-02-28 |
CA2485351A1 (en) | 2003-11-27 |
RU2326867C2 (ru) | 2008-06-20 |
EP1507760B1 (en) | 2007-08-01 |
WO2003097601A1 (en) | 2003-11-27 |
HK1076812A1 (en) | 2006-01-27 |
MXPA04011322A (es) | 2005-02-17 |
ES2290454T3 (es) | 2008-02-16 |
AU2003229534B2 (en) | 2009-08-27 |
JP2005538949A (ja) | 2005-12-22 |
CN1662501A (zh) | 2005-08-31 |
IL165086A0 (en) | 2005-12-18 |
KR20050016412A (ko) | 2005-02-21 |
ATE368649T1 (de) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE455092T1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
ATE408601T1 (de) | Fredericamycin-derivate | |
CY1108067T1 (el) | Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης | |
CY1105137T1 (el) | Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους | |
HK1076812A1 (en) | Cyanoguanidine prodrugs | |
SE0302811D0 (sv) | Novel compounds | |
CY1109422T1 (el) | Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου | |
CY1106405T1 (el) | Παραγωγα κουιναζολινης | |
ATE461217T1 (de) | Glp-1-verbindungen | |
NO20034056D0 (no) | Proliferative sykdommer | |
CY1105221T1 (el) | Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις | |
CY1108874T1 (el) | ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ | |
IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
SE0301650D0 (sv) | Novel compounds | |
UY27451A1 (es) | 2,5-diamidoindoles sustituidos y su utilización | |
SE0202693D0 (sv) | Compounds | |
SE0202692D0 (sv) | Compounds | |
NO20053562L (no) | Nye aminobenzofenonforbindelser | |
CY1110796T1 (el) | Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης | |
CY1110737T1 (el) | Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης | |
ATE321760T1 (de) | N-aryl-2-oxazolidinone und deren derivate | |
DK1551850T3 (da) | 2"-oxo-voruscharin og derivater deraf | |
ATE478155T1 (de) | Glycopeptidantibiotika |